Navigation Links
Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer
Date:6/21/2016

CAMBRIDGE, Mass., June 21, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present new analyses of the Phase 3 NAPOLI-1 data in an oral presentation and poster discussion session at the European Society for Medical Oncology  (ESMO) 18th World Congress on Gastrointestinal Cancer, June 29 – July 2, 2016 in Barcelona, Spain. An oral presentation by Dr. Richard Hubner, Consultant Medical Oncologist, The Christie NHS Foundation Trust and investigator on the NAPOLI-1 trial, will compare the effects of ONIVYDE® (also known as "nal-IRI") in combination with fluorouracil and leucovorin on quality of life in patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-based therapy versus treatment with fluorouracil and leucovorin alone.

Merrimack will also present an analysis of the NAPOLI-1 safety data across patient subgroups in a poster discussion session and a trials-in-progress poster on a Phase 2 study evaluating ONIVYDE containing regimens as first-line therapy for patients with metastatic pancreatic cancer.

Oral Presentation:

  • Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy (Abstract O-004)
    Wednesday, June 29, 2016, 5:53 - 6:03 PM CEST
    Session: Pancreatic Cancer
    Poster Presentation Time: Thursday, June 30, 2016, 11:00 - 11:30 AM and 5:10 - 5:40 PM CEST
    CCIB, Exhibit Hall

Poster Sessions:

  • Safety across subgroups in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy (Abstract PD-023)
    Session: Pancreatic Cancer
    Poster Discussion Time: Thursday, June 30, 2016, 11:00 - 11:30 AM CEST
    Poster Presentation Time: Thursday, June 30, 2016, 11:00 - 11:30 AM and 5:10 - 5:40 PM CEST
    CCIB, Exhibit Hall
  • Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): A randomized, open-label phase 2 study (Abstract P-287)
    Session: Pancreatic Cancer
    Poster Presentation Time: Thursday, June 30, 2016, 11:00 - 11:30 AM and 5:10 - 5:40 PM CEST
    CCIB, Exhibit Hall

About Merrimack

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDE® (irinotecan liposome injection), was approved by the U.S. FDA in October 2015. With four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry. For more information, please visit Merrimack's website at www.merrimack.com or connect on Twitter at @MerrimackPharma.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

Contacts:
Media Contact
Marianne McMorrow
774-776-1478
mmcmorrow@merrimack.com

Investor Contact
Geoffrey Grande, CFA
617-441-7602
ggrande@merrimack.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/merrimack-to-present-new-analyses-of-phase-3-napoli-1-data-at-the-esmo-18th-world-congress-on-gastrointestinal-cancer-300288223.html


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Merrimack Reports Fourth Quarter 2015 Financial Results
2. Merrimack Announces Private Placement of $175 Million of Senior Secured Notes
3. Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to Support Potential Registration
4. Merrimack Reports Third Quarter 2015 Financial Results
5. Merrimack to Present Research on Multiple Programs at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Merrimack Announces Timing of Third Quarter 2015 Investor Conference Call
7. PharmaEngine Announces U.S. FDA Approves Merrimacks ONIVYDE(TM) (irinotecan liposome injection)
8. Merrimack Pharmaceuticals Names Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development
9. Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call
10. Merrimack Pharmaceuticals Announces the Addition of John M. Dineen, Former CEO of GE Healthcare, to Its Board of Directors
11. Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2019)... ... 2019 , ... NATIONAL OFFICE – BKD CPAs & Advisors is pleased to ... the health care practice. Former NIP Eddie Marmouget will transition to a leadership role ... our national health care practice and work more closely with our team to innovate ...
(Date:5/22/2019)... ... May 22, 2019 , ... A leading global health expert urged new ... that celebrates past health care successes and builds on them to make better lives ... professor of global health at the University of Washington and Institute Director of the ...
(Date:5/22/2019)... ... May 22, 2019 , ... The ... well-established healthcare professionals to lead its next three Steven A. Cohen Military ... provided much-needed mental health care to more than 11,000 clients, with a focus ...
Breaking Medicine Technology:
(Date:5/23/2019)... Mass. (PRWEB) , ... May 23, 2019 , ... ... the healthcare industry, today announced that Lean Human Capital has selected the winners ... ninth year Lean Human Capital by HealthcareSource has recognized excellence in healthcare recruitment. ...
(Date:5/23/2019)... ... May 23, 2019 , ... Neurohacker Collective , the ... Emerson Ecologics. Qualia Mind, Qualia Focus, and Qualia Mind Caffeine Free are now ... extensive nearly 40 year history of providing the broadest selection of wellness products, ...
(Date:5/22/2019)... ... ... 5 Design Change Considerations to Stay Compliant , An FDAnews Webinar, Thursday, ... devicemakers read the fine print when changing a design? , Changes are subject to ... t’s may result in inspection failures as well as missed profit opportunities. , Spend ...
(Date:5/22/2019)... ... 22, 2019 , ... In the U.S. in 2014, according to the Society ... last step in the in vitro fertilization (IVF) process. This represents an 83% increase ... P. Trolice, Director of Fertility CARE: The IVF Center , emphasizes that donated ...
(Date:5/22/2019)... , ... May 22, 2019 , ... With record-breaking starting positions, three drivers from ... Ed Jones have qualified their Chevrolets for the team’s entry in the 103rd ... NTT IndyCar Series qualifying run, Pigot was sitting in pole position in his No. 21 ...
Breaking Medicine News(10 mins):